An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

The addition of brentuximab vedotin to lenalidomide and rituximab improved survival ... in each treatment arm developed neutropenia, thrombocytopenia, diarrhea or anemia. Researchers acknowledged ...

Brukinsa plus R-CHOP demonstrated high efficacy and durable responses in double-expressor lymphoma, with manageable safety, supporting further phase 3 trials.

Patients with SMZL often experience lymphocytosis and cytopenias, such as anemia and thrombocytopenia ... only radiotherapy or surgical resection without additional management, rituximab as ...

The FDA has accepted the resubmission of a BLA for odronextamab for the treatment of patients with relapsed/refractory ...

The most common treatment-emergent adverse events (TEAEs) included thrombocytopenia (73% ... including front-line [rituximab, doxorubicin, cyclophosphamide, vincristine and prednisolone (R ...

Future Oncol. 2013;9(3):355-368. While preliminary clinical data are encouraging, the durability of responses observed with treatment with ADC-based regimens remains to be determined. Equally ...

At the moment CAD is managed using off-label therapies, including rituximab and corticosteroid ... other indications including immune thrombocytopenic purpura. Last year, Sanofi recorded late ...

Malignancies of B cells include lymphomas and leukemias. Lymphomas of B-cell origin constitute a diverse set of neoplasms within the larger context of non-Hodgkin's lymphoma (NHL). In the USA, B ...